Evaxion discontinues EVX-03 and refocuses its cancer vaccine pipeline on EVX-05, an off-the-shelf glioblastoma vaccine developed with Duke University.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
Evaxion A/S has expanded and refocused its cancer vaccine pipeline with EVX-05, an off-the-shelf therapeutic vaccine candidate being developed for glioblastoma (GBM), one of the most aggressive primary brain cancers. The candidate uses Evaxion’s proprietary AI-Immunology™ platform to identify conserved endogenous retrovirus (ERV)-derived antigens shared between glioblastoma patients.
The strategy is intended to support development of a vaccine that can potentially be used across multiple patients rather than requiring individualized vaccine manufacturing.
AI Platform Identifies Conserved ERV-Derived Targets
EVX-05 is designed around ERV-derived antigens that Evaxion has identified as potential shared targets across glioblastoma patients. The company considers these antigens a novel source of targets for off-the-shelf cancer vaccines.
The program reflects Evaxion’s broader strategy of applying AI-based target discovery to cancers where immunotherapy remains inadequate. Unlike personalized cancer vaccines, EVX-05 is being developed around conserved targets, potentially allowing a single vaccine approach to be evaluated across a broader patient population.
However, EVX-05 remains an investigational program, and its ability to generate clinically meaningful antitumor responses has not yet been established in humans.
Duke University Collaboration to Support Development
Evaxion is collaborating with experts from Duke University School of Medicine to advance EVX-05. Professor Mustafa Khasraw, M.D., and his team are expected to contribute their glioblastoma research and clinical expertise as the program progresses toward initial clinical testing.
Evaxion is currently optimizing a lead vaccine candidate. The collaboration could potentially provide a cost-efficient pathway toward a Phase 1 clinical study, although EVX-05 has not yet entered clinical trials.
EVX-05 Builds on EVX-04 Strategy
The new program builds on the same ERV-targeting concept used in EVX-04, Evaxion’s off-the-shelf cancer vaccine candidate targeting acute myeloid leukemia (AML).
According to the company, the two programs demonstrate the potential applicability of the ERV-targeting approach across cancers where conserved immunogenic antigens can be identified and existing immunotherapy options remain inadequate.
Both EVX-05 and EVX-04 also draw on learnings from the company’s EVX-03 program.
EVX-03 Discontinued as Pipeline Is Reprioritized
The addition of EVX-05 comes alongside the discontinuation of EVX-03 as part of Evaxion’s portfolio management and R&D refocusing. EVX-03 has been removed from the company’s development pipeline.
Evaxion stated that the costs associated with EVX-05 are covered within its existing budgets and therefore do not affect its expected cash runway, which extends into the second half of 2027.
This allows the company to introduce EVX-05 while maintaining its stated financial runway and concentrating development resources on selected vaccine programs.
Clinical Development Remains the Key Next Step
EVX-05 is currently in lead candidate optimization and has not yet generated human clinical efficacy data. The immediate priority is to complete optimization and advance the program toward initial clinical testing.
Future clinical studies will need to establish the vaccine’s safety, immune response and potential antitumor activity in patients with glioblastoma. Evaxion’s management is scheduled to discuss EVX-05 during its Q2 2026 business update and financial results webcast on August 20, 2026.
The addition of EVX-05, together with the discontinuation of EVX-03, marks a clear reprioritization of Evaxion’s cancer vaccine pipeline toward selected programs built around its AI-driven antigen discovery and off-the-shelf vaccine strategy.
References
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.